Cediranib

• Description:

  Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

• Product Name Alternative:

  AZD2171

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; PDGFR; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Cediranib.html

• Purity:

  99.87

• Solubility:

  DMSO : 20 mg/mL (ultrasonic)

• Smiles:

  FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5

• Molecular Formula:

  C25H27FN4O3

• Molecular Weight:

  450.51

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65 (10), 4389-4400.|[2]Zhang L, et al. Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci Signal. 2015 Dec 8;8 (406) :ra125.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• Isoform:

  PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4

• Citation 01:

  Biomaterials. 2018 Apr;161:164-178. |Biomed Res Int. 2021 Mar 29:2021:5582648.|Cell Stem Cell. 2019 Sep 5;25 (3) :373-387.e9.|Discov Oncol. 2024 Nov 19;15 (1) :678.|Eur J Pharmacol. 2024 Feb 5:964:176278.|Harvard Medical School LINCS LIBRARY|J Med Chem. 2023 Dec 28;66 (24) :16597-16614.|Neuro Oncol. 2016 Apr;18 (4) :538-48. |Sci Signal. 2015 Dec 8;8 (406) :ra125. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Life Sci. 2024 Jun 23:122862.

• CAS Number:

  [288383-20-0]